Single Comparative Study of Magnetic Stimulation for Neuropathic Pain

Single Comparative Study Confirming the Effectiveness of Magnetic Stimulation for Neuropathic Pain including Minamata Disease Patients

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCTs072200021

Enrollment

Registered

2020-07-15

Start date

2021-04-27

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Neuropathic pain patients including Minamata disease Minamata disease, Neuropathic pain

Interventions

Using High Frequency Transcranial Magnetic Stimulator (MagPro X100, Mag Venture), magnetic stimulation therapy is performed a total of 5 times for 5 consecutive days.

Magnetic stimulation therapy

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Age at the time of consent acquisition: 50 years old or older / Gender: No matter / ADL: Relatively maintained / Not excluded by TMS registration form / Neuropathic pain had been continuing for 6 months or more at the time of consent obtained / The average value of VAS for one week during the screening period is 4.0 or more / The VAS could be recorded for one week during the screening period

Exclusion criteria

Exclusion criteria: Those who cannot obtain written consent for this study / Those who meet the eligibility criteria but their attending physicians have determined that it is impossible for them to enrolled in the clinical study / Those with diabetic neuropathy / Those for whome 3T MRI examination cannot be performed / Those with cognitive decline (MMSE<24) / Pregnant or potentially pregnant

Design outcomes

Primary

Measure	Time frame
Amount of change of the mean VAS score for one week after the end of treatment from baseline VAS score. Baseline VAS score : Mean VAS score performed for 1 week before treatment.	—

Secondary

Measure	Time frame
Amount of change of the mean VAS score for each week of 2nd, 3rd, and 4th week after the treatment from baseline VAS score. Amount of change of the pain threshold in transcranial magnetic stimulation treatment at each time point (immediately after 5th day-treatment, 28 days after treatment). Amount of change of the pain evaluation scale (SF-MPQ-2) at each time point (immediately after 5th day-treatment, 28 days after treatment). Amount of change of Beck Depression Inventory (BDI) at each time point of (immediately after 5th day-treatment, 28 days after treatment). Satisfaction with treatment (PGIC) at immediately after 5th day-treatment and 28 days after treatment. Amount of change of VAS score from the pre-treatment value in the days during the treatment period (1st - 5th day).	—

Measure

Time frame

Amount of change of the mean VAS score for each week of 2nd, 3rd, and 4th week after the treatment from baseline VAS score. Amount of change of the pain threshold in transcranial magnetic stimulation treatment at each time point (immediately after 5th day-treatment, 28 days after treatment). Amount of change of the pain evaluation scale (SF-MPQ-2) at each time point (immediately after 5th day-treatment, 28 days after treatment). Amount of change of Beck Depression Inventory (BDI) at each time point of (immediately after 5th day-treatment, 28 days after treatment). Satisfaction with treatment (PGIC) at immediately after 5th day-treatment and 28 days after treatment. Amount of change of VAS score from the pre-treatment value in the days during the treatment period (1st - 5th day).

—

Contacts

Public ContactNobuko Tabata

National Institute for Minamata Disease

NOBUKO_TABATA@env.go.jp+81-966-63-3111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026